Delivery systems for biologics
European Pharmaceutical Review
MARCH 4, 2024
Therefore, biologics identification and characterisation poses unparalleled challenges, as does their manufacturing processes and routes of administration while maintaining patient safety and clinical efficacy. Notably, LNPs facilitate the transportation of large payloads, have limited immunogenicity, and allow for scalable manufacturing.
Let's personalize your content